Introduction of TAK-003 Dengue Vaccine in India

India’s dengue vaccination journey has reached a significant milestone with the approval of Takeda’s tetravalent dengue vaccine, TAK-003 or Qdenga, for individuals aged 4 to 60 years. This vaccine has been evaluated in trials involving over 28,000 participants and approved in over 40 countries. It promises to change the approach from reactive vector control to preventive vaccination, marking a significant step in combating dengue.

Advantages of TAK-003

• Evaluated in large global trials with more than 28,000 participants.
• Approved in over 40 countries.
• No requirement for pre-vaccination screening for prior dengue infection.
• Demonstrates good safety and strong protection against severe dengue and hospitalization.

Challenges and Limitations

The vaccine’s efficacy varies across different dengue serotypes:

• Strong performance against DENV-2, but lower effectiveness against DENV-3 and DENV-4.
• India’s evolving dengue epidemiology shows increasing cases of DENV-3, potentially impacting vaccine effectiveness at the population level.
• TAK-003 is likely to reduce disease severity rather than prevent infection, necessitating continued vector control measures.

Cost and Accessibility

• The vaccine is costly, with prices expected to be Rs 3,000-6,000 per dose and Rs 6,000-12,000 for the full course.
• Potential limited uptake in the initial years, primarily in the private sector or targeted high-burden areas.
• Affordability and compliance challenges, particularly for lower-income and rural populations.

Future Perspectives and Developments

The SEC has mandated post-marketing safety and effectiveness studies, crucial for understanding the vaccine’s performance in diverse Indian conditions. Looking forward:

• A second generation of vaccines, based on NIH’s TV003 platform, is undergoing evaluation.
• An indigenous candidate, DengiAll, developed by Panacea Biotec, is in phase III trials, aiming for balanced protection across all serotypes.
• Potential availability of more effective vaccines by 2027, offering single-dose regimens and broader serotype coverage.

Conclusion

For policymakers, balancing the immediate need to reduce severe dengue with the long-term strategy of adopting better vaccines as evidence evolves is crucial. Clinicians must ensure clear communication about the vaccine's realistic benefits. The introduction of a dengue vaccine should be seen as the beginning of a new phase in combating dengue, with TAK-003 being a valuable tool, though not the final answer.